OXERVATE eye drops show promise for Long-Term corneal healing in rare eye disease

NCT ID NCT05552261

Completed Disease control Sponsor: Dompé Farmaceutici S.p.A Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 24 people with stage 1 neurotrophic keratitis, a rare eye condition that can damage the cornea, who had previously used OXERVATE eye drops in an earlier study. Researchers checked if the cornea stayed healed up to 30 months after treatment. The goal was to see if the medicine's effects last long-term and to monitor safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cenegermin (OXERVATE) eye drops
What this could lead to: If successful, this could show that OXERVATE helps maintain corneal healing for up to 30 months in people with neurotrophic keratitis.
What could go wrong: This is a small extension study with only 24 participants and no new treatment given, so results may not apply to everyone. Long-term benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROTROPHIC KERATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neurotrophic keratopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROTROPHIC KERATITIS

Contacts and locations

Locations

Cincinnati Eye Institute

Edgewood, Kentucky, 41017, United States
New Vision Institute

San Diego, California, 92037, United States
Scheie Eye Institute

Philadelphia, Pennsylvania, 19104, United States
Tufts Medical Center

Boston, Massachusetts, 02011, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.